Key Insights

Highlights

Success Rate

75% trial completion

Treatment Research

9 treatments under study, led by Persona Total Knee

Related Conditions

Often studied with 5 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 52/100

Termination Rate

25.0%

1 terminated out of 4 trials

Success Rate

75.0%

-11.6% vs benchmark

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

67%

2 of 3 completed with results

Key Signals

2 with results75% success

Data Visualizations

Phase Distribution

4Total
Not Applicable (3)
Phase 3 (1)

Trial Status

Completed3
Terminated1

Trial Success Rate

75.0%

Benchmark: 86.6%

Based on 3 completed trials

Clinical Trials (4)

Showing 4 of 4 trials
NCT04338893Not ApplicableCompleted

ROSA Total Knee Post Market Study EMEA

NCT03969654Not ApplicableCompleted

ROSA Robot Used in Total Knee Replacement Post Market Study

NCT03970629Not ApplicableTerminated

ROSA Total Knee Investigational Testing Authorization Study

NCT00902837Phase 3CompletedPrimary

OXN PR Compared to OxyPR to Demonstrate Non-inferiority in Pain & Locomotor Function & Improvement in Symptoms of Constipation in OA Subjects

Showing all 4 trials

Research Network

Common Treatments

  • Persona Total Knee2
  • Oxycodone Naloxone Tablet1
  • Device Nexgen Total Knee1
  • Vanguard Total Knee1
  • Oxycodone Naloxone Prolonged Release Tablets Oxn1

Active Sponsors

  • Zimmer Biomet3
  • Mundipharma Research GmbH & Co KG1

Top Investigators

Related Conditions

  • Moderate Varus Valgus Or Flexion Deformities3
  • Rheumatoid Arthritis3
  • Knee Pain3
  • Avascular Necrosis Of The Femoral Condyle2
  • Avascular Necrosis Of Femoral Condyle1

Activity Timeline